Clinical trials testing the effects of combination therapy involving two ICIs, anti-CTLA-4 and anti-PD-1, have shown promising results in cancers like melanoma and have already been approved by the FDA for clinical use [89], and other trials using combinations of relatlimab (anti-LAG-3 antibody) and nivolumab are already underway [90]. This evidence concerns the gene PDCD1 and melanoma.